Pfizer-White House deal prompts pharma rally on Wall Streetnews2025-10-01T19:48:48+00:00October 1st, 2025|Endpoints News|
Biogen owes Genentech $88M in royalties from Tysabri, court rulesnews2025-10-01T19:24:10+00:00October 1st, 2025|Endpoints News|
Trump’s 100% pharma tariff won’t start Oct. 1, White House confirmsnews2025-10-01T18:04:52+00:00October 1st, 2025|Endpoints News|
Exclusive: French startup’s gene therapy dramatically reduces urinary incontinence in spinal cord injury patientsnews2025-10-01T15:08:15+00:00October 1st, 2025|Endpoints News|
Halozyme to spend $750M upfront to buy Elektrofi, a biologics tech delivery companynews2025-10-01T14:43:46+00:00October 1st, 2025|Endpoints News|
Enanta aims to raise $50M as it advances RSV therapy; Hinge, Kyorin make a dealnews2025-10-01T14:17:17+00:00October 1st, 2025|Endpoints News|
Post-Hoc Live: Unpacking Trump and Pfizer’s ‘most favored nation’ dealnews2025-10-01T13:34:35+00:00October 1st, 2025|Endpoints News|
FDA rejects treatment for rare copper deficiency over manufacturingnews2025-10-01T13:17:23+00:00October 1st, 2025|Endpoints News|
Ansa Biotechnologies closes $54.4M Series B to boost US DNA manufacturing news2025-10-01T12:00:10+00:00October 1st, 2025|Endpoints News|
